AYTU BioScience   Report issue

Contributed to NME For profit Phase 3
Founded: Englewood CO United States (2002)
Status: Acquired by Neos Therapeutics, Inc (2021)

Organization Overview

First Clinical Trial
2024
NCT05463679
First Marketed Drug
2002
capromab pendetide (Prostascint)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AYTU | AYTU BIOPHARMA | Aytu BioPharma, Inc. | Aytu BioScience, Inc.

Active Ingredients

Marketed Drugs (10)

Key: AYTU BioScience (9) Acquired (1)

amphetamine (Adderall) (2016)

capromab pendetide (Prostascint) (1996 NDA)

carbinoxamine maleate (clistin) (2013)

chlorpheniramine (ChlorTrimeton) (2015)

codeine (Phenergan) (2015)

hydrocodone (hycodan) (2012)

methylphenidate (ritalin) (2001)

rabeprazole (pariet) (2013)

testosterone (delatestryl) (2014)

zolpidem (ambien) (2008)

Drugs in Phase 3 Trials (2)

Key: AYTU BioScience (0) Acquired (2)

enzastaurin (1 trial)

methylphenidate (ritalin) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 2
  • # of Trial APIs: 2